Cipher Pharmaceuticals, Inc. (CPHR) - NASDAQ
  • Thu, May 5, 7:11 AM
    • Cipher (NASDAQ:CPHR): Q1 EPS of -$0.10 misses by $0.06.
    • Revenue of $9.1M (+23.0% Y/Y) misses by $1.62M.
    • Press Release
    | Thu, May 5, 7:11 AM
  • Mon, May 2, 11:20 AM
    • Cipher Pharmaceuticals (CPHR +0.2%) licenses the worldwide rights to develop and commercialize an investigational tattoo removal cream being developed at Dalhousie University in Halifax, Nova Scotia. The liposome cream penetrates the skin and destroys the macrophages (type of white blood cell) containing the tattoo pigment, which fades the image. Its value proposition is pain-free removal, a profound advantage compared to laser treatment. It could potentially replace laser removal, but could also be positioned as adjunct therapy to reduce the frequency and cost of laser treatment.
    • Financial terms are not disclosed.
    | Mon, May 2, 11:20 AM
  • Wed, Feb. 24, 10:53 AM
    • Cipher Pharmaceuticals (CPHR -4.9%) Q4 results: Revenues: $9.7M (+29.3%); R&D Expense: $0.8M (+166.7%); SG&A: $8.3M (+196.4%); Net Income: $2M (-37.5%); EPS: $0.08 (-33.3%).
    • FY2015 results: Revenues: $34.4M (+17.8%); R&D Expense: $2.1M (+90.9%); SG&A: $25.4M (+182.2%); Net Income: $1.8M (-90.4%); EPS: $0.07 (-90.5%).
    • No guidance given.
    | Wed, Feb. 24, 10:53 AM
  • Wed, Feb. 24, 7:12 AM
    • Cipher (NASDAQ:CPHR): Q4 EPS of $0.08 may not be comparable to consensus of $0.00.
    • Revenue of $9.7M (+29.3% Y/Y) beats by $0.39M.
    • Press Release
    | Wed, Feb. 24, 7:12 AM
  • Mon, Feb. 1, 9:35 AM
    • ANI Pharmaceuticals (ANIP +1.4%) acquires exclusive rights to distribute 1% and 2.5% hydrocortisone cream for rectal use and a generic version of Cipher Pharmaceuticals' (CPHRLipofen (fenofibrate capsules, 50 mg and 150 mg), from H-2 Pharma, LLC for $10M. The transaction also includes an undisclosed early-stage generic injectable.
    • Last year, generic Lipofen generated $21.9M in sales through licensee Kowa Pharmaceuticals America. ANI will earn a royalty of 7.5% of net profits while the product is transitioned to ANI, who will launch it under its own label in Q2.
    • The combined market for the hydrocortisone cream is $73M. ANI will launch both strengths in Q2 as well. It will retain a portion of the net profits from all sales.
    | Mon, Feb. 1, 9:35 AM
  • Dec. 10, 2015, 12:13 PM
    • Health Canada approves Cipher Pharmaceuticals' (CPHR +2%) Beteflam (betamethasone valerate topical patch) for the treatment of mild-to-moderate plaque psoriasis of the elbows and knees for a maximum of 30 days in adult patients. The agency accepted the company's application for review in February.
    • Topical corticosteroids are the primary treatment for inflammatory skin conditions that respond to steroids. Psoriasis affects ~1M Canadians.
    | Dec. 10, 2015, 12:13 PM
  • Nov. 30, 2015, 12:49 PM
     
    | Nov. 30, 2015, 12:49 PM | 8 Comments
  • Nov. 4, 2015, 7:27 AM
    • Cipher (NASDAQ:CPHR): Q3 EPS of -$0.09
    • Revenue of $8.5M (+28.8% Y/Y)
    | Nov. 4, 2015, 7:27 AM
  • Oct. 5, 2015, 12:46 PM
    | Oct. 5, 2015, 12:46 PM | 2 Comments
  • Aug. 14, 2015, 9:23 AM
    • Cipher (NASDAQ:CPHR): Q2 EPS of -$0.02
    • Revenue of $8.8M (+10.0% Y/Y)
    • Shares +3.2% PM.
    | Aug. 14, 2015, 9:23 AM
  • Aug. 4, 2015, 9:41 AM
    • The FDA accepts for review Cipher Pharmaceuticals' (NASDAQ:CPHR) 510(k) submission seeking approval for its Dermadexin topical barrier-repair cream for the treatment seborrheic dermatitis.
    • Cipher acquired the rights to Dermadexin, as well as the candidates Pruridexin and ASF-1096, from Denmark's Astion Pharma in February. All three focus on inflammatory dermatological diseases.
    • In 2014, Dermadexin was cleared in the European Union for the alleviation of symptoms of facial dermatitis.
    | Aug. 4, 2015, 9:41 AM
  • May 19, 2015, 12:47 PM
    | May 19, 2015, 12:47 PM | 3 Comments
  • May 13, 2015, 7:03 AM
    • Cipher (NASDAQ:CPHR): Q1 EPS of C$0.12
    • Revenue of C$9.18M (+16.5% Y/Y)
    | May 13, 2015, 7:03 AM
  • Apr. 13, 2015, 12:44 PM
    | Apr. 13, 2015, 12:44 PM
  • Apr. 13, 2015, 9:55 AM
    • Cipher Pharmaceuticals (CPHR +15.1%) acquires privately-held Innocutis Holdings LLC for $45.5M in cash. The dermatology firm posted more than $10M in sales in 2014. Cipher expects the deal to be accretive to earnings within two years.
    • Cipher President & CEO Joe Pecora says, "Today's transaction marks or commercial entry to the U.S. market and represents an important step toward our goal of creating a leading North American dermatology business. Innocutis provides us with commercial infrastructure, revenue-generating branded prescription products and a talented team, including a 31-person sales force, that shares our customer-focused philosophy."
    | Apr. 13, 2015, 9:55 AM | 1 Comment
  • Mar. 23, 2015, 9:52 AM
    • Israeli firm Can-Fite BioPharma (CANF +6.4%) signs a distribution agreement with Cipher Pharmaceuticals (CPHR -0.3%) to distribute the former's lead product candidate, CF101, in Canada after regulatory approval.
    • Under the terms of the agreement, Can-Fite will receive an upfront payment of CDN$1.65M, up to CDN$2M in milestones and a royalty of 16.5% on net sales.
    • CF101, an A3 adenosine receptor agonist, is an orally available small molecule drug being developed for the treatment of inflammatory diseases.
    | Mar. 23, 2015, 9:52 AM
Company Description
Cipher Pharmaceuticals Ltd. is a pharmaceutical company, which is focused on commercializing novel formulations of marketed molecules by using advanced drug delivery technologies. The company has three in-licensed products, which includes Lipofen, Conzip/Durela and CIP-ISOTRETINOIN. The Lipofen... More
Sector: Healthcare
Industry: Drug Related Products
Country: Canada